Litcius/Paper detail

Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.

John G. Rizk, Donald N. Forthal, Kamyar Kalantar‐Zadeh, Mandeep R. Mehra, Carl J. Lavie, Youssef Rizk, J Pfeiffer, John C. Lewin

2020Drug Discovery Today81 citationsDOIOpen Access PDF

Topics & Concepts

Compassionate UsePandemicExpanded accessMedicineCoronavirus disease 2019 (COVID-19)HydroxychloroquineClinical trialAuthorizationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineDrugCoronavirusVirologyInfectious disease (medical specialty)PharmacologyDiseaseComputer securityOncologyInternal medicineComputer scienceBiomedical Ethics and RegulationPharmaceutical studies and practicesLong-Term Effects of COVID-19
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. | Litcius